Photo from Novartis' Indianapolis plant (Credit: Novartis)

Lutetium, ac­tini­um or lead: Can iso­tope type of­fer an edge in ra­dio­ther­a­py?

Once con­sid­ered a niche can­cer ther­a­py, ra­di­oli­gands are in the midst of a re­nais­sance.

“If you think about where AD­Cs were four or five years …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.